Research programme: prophylactic malaria vaccines - Genocea Biosciences

Drug Profile

Research programme: prophylactic malaria vaccines - Genocea Biosciences

Alternative Names: GEN-005; T cell antigen malaria vaccine - Genocea Biosciences

Latest Information Update: 20 Nov 2015

Price : $50

At a glance

  • Originator Genocea Biosciences
  • Developer Genocea Biosciences; Naval Medical Research Center
  • Class Parasitic vaccines; Protein-vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Malaria

Most Recent Events

  • 06 May 2015 Genocea plans preclinical studies for Malaria (Genocea Biosciences 10-K, May 2015)
  • 23 Sep 2014 Research is ongoing for Malaria
  • 06 Sep 2013 Isconova is now called Novavax AB
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top